Mark C. McKenna
CIK: 0001749623
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Sep 3, 2026APGE
Apogee Therapeutics, Inc.
Disposition(D)Direct20K shares- - Jul 20, 2026FRNM
Freenome, Inc.
Conversion(C)Direct30K shares- - Jun 9, 2026APGE
Apogee Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
7.7K shares- - May 27, 2026SYRE
Spyre Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
8K shares- - Jan 7, 2026NAMS
NewAmsterdam Pharma Co N.V.
Award(A)Direct3.4K shares- - Aug 11, 2025BBOT
BridgeBio Oncology Therapeutics, Inc.
Exercise(M)Direct30K shares- - Jun 17, 2025APGE
Apogee Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
14.5K shares- - May 29, 2025SYRE
Spyre Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
25K shares- - Jan 7, 2025NAMS
NewAmsterdam Pharma Co N.V.
Award(A)Direct7K shares- - Jan 6, 2025NAMS
NewAmsterdam Pharma Co N.V.
Award(A)DirectOption (right to buy)
32.5K shares- - Dec 12, 2024APGE
Apogee Therapeutics, Inc.
Purchase(P)Direct12.5K shares at avg. $49.85$623K - Dec 12, 2024APGE
Apogee Therapeutics, Inc.
Purchase(P)Direct7.5K shares at avg. $49.02$368K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 3, 2026 |  APGE Apogee Therapeutics, Inc. | Disposition(D) | 20,000 | - | $0 | Direct |
| Jul 20, 2026 |  FRNM Freenome, Inc. | Conversion(C) | 30,000 | - | $0 | Direct |
| Jun 9, 2026 | APGE Apogee Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 7,657 | - | - | Direct |
| May 27, 2026 |  SYRE Spyre Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 8,026 | - | - | Direct |
| Jan 7, 2026 |  NAMS NewAmsterdam Pharma Co N.V. | Award(A) | 3,400 | - | $0 | Direct |
| Aug 11, 2025 |  BBOT BridgeBio Oncology Therapeutics, Inc. | Exercise(M) | 30,000 | - | - | Direct |
| Jun 17, 2025 | APGE Apogee Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 14,461 | - | - | Direct |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 25,000 | - | - | Direct |
| Jan 7, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) | 6,960 | - | $0 | Direct |
| Jan 6, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) Option (right to buy) | 32,500 | - | - | Direct |
| Dec 12, 2024 | APGE Apogee Therapeutics, Inc. | Purchase(P) | 12,500 | $49.85 | $623,125 | Direct |
| Dec 12, 2024 | APGE Apogee Therapeutics, Inc. | Purchase(P) | 7,500 | $49.02 | $367,650 | Direct |
1-12 of 12 transactions
About McKenna Mark C.
McKenna Mark C. (SEC CIK 0001749623) files insider reports with the SEC as Director of TCGX Acquisition Corp. II (TCXB), Director of Apogee Therapeutics, Inc. (APGE) and Freenome, Inc. (FRNM). Signal8 also holds filings tied to 4 other companies.
Signal8 holds 12 ownership filings by McKenna Mark C. (2 Form 3, 10 Form 4), filed between Dec 16, 2024 and Oct 20, 2026. Those filings report 12 transactions, from Dec 12, 2024 to Sep 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on McKenna Mark C.'s filings is in PALO ALTO, CA.
Recent filings by McKenna Mark C.
- Sep 3, 2026: Disposition to issuer transaction of APGE shares (Form 4, code D).
- Jul 20, 2026: Conversion of FRNM shares (Form 4, code C).
- Jun 9, 2026: Grant or award of APGE derivative securities (Form 4, code A).
- May 27, 2026: Grant or award of SYRE derivative securities (Form 4, code A).
- Jan 7, 2026: Grant or award of NAMS shares (Form 4, code A).
Other insiders filing for TCGX Acquisition Corp. II (TCXB)
- Yu Chen-Ming, Chief Executive Officer
- HENDERSON MICHAEL THOMAS, Director
- Cohen Joshua B, Director
- Skaling Craig David, Chief Financial Officer